FIGURE SUMMARY
Title

Curcumae Rhizoma - combined with Sparganii Rhizoma in the treatment of liver cancer: Chemical analysis using UPLC-LTQ-Orbitrap MSn, network analysis, and experimental assessment

Authors
Wei, J., Wang, X., Dong, Y., Zhong, X., Ren, X., Song, R., Ma, J., Yu, A., Fan, Q., Yao, J., Shan, D., Lv, F., Zheng, Y., Deng, Q., Li, X., He, Y., Fan, S., Zhao, C., Wang, X., Yuan, R., She, G.
Source
Full text @ Front Pharmacol
FIGURE 1

Flow chart of the study process.
FIGURE 2

MS/MS molecular networking of the CR-SR decoction in the positive mode. The novel compound is in red, and its name and structure are depicted in the left column. The known compound is in yellow, and the name is depicted in the right column.

FIGURE 3

MS/MS molecular networking of the SR decoction in the positive mode. The novel compound is in red, and its name and structure are depicted in the left column. The known compound is in yellow, and the name is depicted in the right column.

FIGURE 4

TIC chromatograms in the positive mode; (A) CR-SR extract, (B) CR extract, and (C) SR extract.

FIGURE 5

TIC chromatograms in the negative mode; (A) CR-SR extract, (B) CR extract, and (C) SR extract.

FIGURE 6

The structures of sesquiterpenoids and cyclic dipeptides identified in CR-SR, CR, and SR extracts.

FIGURE 7

Network pharmacology of CR-SR in liver cancer treatment. (A) Venn diagram of active compound targets of CR-SR, CR, SR with liver cancer targets. (B) Active compound-target network of the overlapping targets between CR-SR and liver cancer (targets as orange diamond nodes; diarylheptanoids as blue circle nodes; phenols and organic acids as green circle nodes; sesquiterpenoids as purple circle nodes; cyclic dipeptides as yellow circle nodes. (C) The PPI network of the screening targets. (D) Go enrichment analysis (top 10). (E) Bubble diagram of enrichment analysis of KEGG pathway (top 20).

FIGURE 8

Active compound-key target-pathway network of CR-SR for liver cancer, where green nodes resented active compounds, blue nodes denoted key targets, and orange nodes indicated enriched pathway.

FIGURE 9

Molecular docking. (A) Binding modes of 3,5-diacetoxy-1-(3,4-dihydroxyphenyl)-7-(4-hydroxyphenyl)-heptane in the SRC-binding pocket. (B) Binding modes of 3,5-diacetoxy-1-(3,4-dihydroxyphenyl)-7-(4-hydroxyphenyl)-heptane in the EGFR-binding pocket. (C) Binding modes of 3,5-diacetoxy-1-(3,4-dihydroxyphenyl)-7-(4-hydroxyphenyl)-heptane in the ESR1-binding pocket. (D) Binding modes of 1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-4,6-dien-3-one in the PTGS2-binding pocket.

FIGURE 10

Inhibitory effects on the proliferation rate of HepG2 cells. **p < 0.01 compared with the model group. (A) Chart of CR-SR, (B) chart of CR, (C) chart of SR, and (D) line chart of CR-SR, CR, and SR.

FIGURE 11

Activity of anti-liver cancer in the zebrafish HepG2 xenograft model. (A) Dose–toxicity curves in 3–6 dpf zebrafish. (B) Effects of CR-SR, CR, and SR on the tumor area in zebrafish (×40). (C) Inhibition rates of the CR-SR, CR, and SR groups. **p < 0.01 compared with the model group.

FIGURE 12

Expression of SRC, EGFR, ESR1, PTGS2, and APP in zebrafish larvae was detected by RT-qPCR

Acknowledgments
This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Front Pharmacol
Your Input Welcome
We welcome your input and comments. Please use this form to recommend updates to the information in ZFIN. We appreciate as much detail as possible and references as appropriate. We will review your comments promptly.
Please check the highlighted fields and try again.
Thank you for submitting comments. Your input has been emailed to ZFIN curators who may contact you if additional information is required.
Oops. Something went wrong. Please try again later.